GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

JS002

Company
Shanghai Junshi Bioscience Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for JS002 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05621070

    Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 582 participants Est. completion 2024-09-30 1 site Stand-alone
    Other conditions: Primary Hypercholesterolaemia and Mixed Dyslipidemia
    View official trial listing →
  • Completed NCT NCT04197817

    A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 84 participants Est. completion 2018-08-14 1 site
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT04469673

    A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

    Not yet reported, Not yet reported Shanghai Junshi Bioscience Co., Ltd. 90 participants Est. completion 2020-06-28 1 site Stand-alone
    Other conditions: Hyperlipemia
    View official trial listing →
  • Completed NCT NCT04515927

    To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 31 participants Est. completion 2022-07-29 1 site Stand-alone
    Other conditions: Hyperlipemia
    View official trial listing →
  • Completed NCT NCT04781114

    The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 806 participants Est. completion 2023-01-16 57 sites Stand-alone
    Other conditions: Hyperlipemia
    View official trial listing →
  • Terminated NCT NCT05128539

    A Study Explore JS001+JS002 in Patients With Advanced Cancer

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 9 participants Est. completion 2023-11-10 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT05325203

    A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 135 participants Est. completion 2023-06-29 1 site Stand-alone
    Other conditions: Heterozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT05532800

    The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 255 participants Est. completion 2023-02-09 21 sites Stand-alone
    Other conditions: Hyperlipemia
    View official trial listing →
  • Completed NCT NCT05859529

    A Pharmacokinetic Study of JS002 in Healthy Subjects

    Not yet reported Shanghai Junshi Bioscience Co., Ltd. 318 participants Est. completion 2023-09-11 1 site Stand-alone
    Other conditions: Health Volunteer
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.